Policy & Regulation
Sanaregen receives FDA clearance for retinal degeneration clinical trial
3 March 2026 - Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, on Tuesday announced US Food and Drug Administration (FDA) clearance to begin a Phase I/II clinical trial ...
Lynk Pharmaceuticals reveals positive topline results from zemprocitinib Phase III clinical trial
3 March 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company, on Monday reported positive topline results from its Phase III clinical trial evaluating zemprocitinib...
ReviR Therapeutics doses first participant in First-in-Human Phase 1 clinical trial of RTX-117
3 March 2026 - Clinical-stage biotechnology company ReviR Therapeutics announced on Monday that the first participant has been dosed in the First-in-Human (FIH) Phase 1 clinical trial of its lead cand...
Ono Pharmaceutical expands multi-target research collaboration with Congruence Therapeutics
3 March 2026 - Japan-based Ono Pharmaceutical Co Ltd announced on Monday an expansion of its multi-target research collaboration with Canadian biotechnology company Congruence Therapeutics.The expande...
United Therapeutics' ralinepag reduces risk of clinical worsening in pivotal PAH study
2 March 2026 - Biotechnology company United Therapeutics Corporation (Nasdaq:UTHR) announced on Monday that its long-term pivotal phase 3 ADVANCE OUTCOMES study of ralinepag met the primary endpoint, ...
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
2 March 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that its Phase III FENhance 1 study in relapsing multiple sclerosis (RMS)...